Clinical Observation of Bevacizumab Combined with TP Regimen and Concurrent Radiotherapy for Recurrent Cervical Cancer
Objective To investigate the efficacy of Bevacizumab combined with TP regimen and concurrent radiothera-py in the treatment of recurrent cervical cancer.Methods A total of 200 patients with recurrent cervical cancer were selected as the study objects and grouped according to the treatment method.The patients in the control group were treated with TP regimen and concurrent radiotherapy,and the patients in the observation group were treated with Bevacizumab combined with TP regimen and concurrent radiotherapy.The therapeutic effects of the two groups were compared.Results The effective rate of treatment in the observation group was 82.22％(74/90),which was higher than 64.55％(71/110)in the control group(P＜0.05);after treatment,the levels of serum squamous cell carcinoma associated antigen(SCC-Ag),carcinoembryonic antigen(CEA)and cell Keratin 19 fragment antigen 21-1(CYFRA21-1)in the two groups were decreased compared with those before treatment(P＜0.05),and the levels in the observation group were lower than those in the control group(P＜0.05);during the treatment period,there was no statistically great difference in the incidence of grade 3-4 side reactions between the two groups(P＞0.05).Conclu-sion Bevacizumab in the treatment of recurrent cervical cancer can improve the efficacy,reduce the level of serum tumor mark-ers,and has good safety in patients with recurrent cervical cancer undergoing TP regimen and simultaneous radiotherapy.
NETL
NSTL
万方数据
